Catalog Products » Recombinant Proteins » Growth Factors » Erythropoietin (EPO), Human
 
Search by Catalog Number :
Search by Name :
Search by Sequence : (One letter code)
Search by Category :



Erythropoietin (EPO), Human



Cat. No.
Name
Size   
Price
Selected
Z02975-1
1 mg
$695

Protein Erythropoietin (EPO), Human
Abbreviated Name-1
Human EPO-alpha, EPO-alpha, EPO alpha, EPOalpha, h-EPO-alpha, rh-AEPO-alpha, recombinant human EPO-alpha, recombinant EPO-alpha, EPO.
Documents
EPO, HumanDocument-MSDS: Z02975_MSDS.pdf (pdf)
Species
Human
Purity
> 95% as analyzed by SDS-PAGE and HPLC.
Endotoxin Level
<0.2 EU/μg, determined by LAL method.
Biological Activity
ED50< 1 ng/ml, measured in a cell proliferation assay using TF-1 human erythroleukemic cells, corresponding to a specific activity of >1 x 106units/mg
Source
CHO
Amino Acid Sequence
Ala28-Arg193(Accession # CAA26094)
Molecular Weight
Mature human EPO, containing 166 amino acid residues, has a predicted molecular mass of approximately 21 kDa. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 26-36 kDa in SDS-PAGE.
Description
Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.
The cDNAs for EPO have been cloned from human, mouse, canine, etc. The mature proteins from the various species are highly conserved, exhibiting greater than 80% sequence identity at the amino acid level. Human EPO cDNA encodes a 193 amino acid residue precursor protein that is processed to yield a 165 amino acid residue mature protein. EPO contains one O-linked and three N-linked glycosylation sites. Glycosylation of EPO is required for EPO biological activities in vivo. EPO exhibits structural as well as amino sequence identity to the amino terminal 153 amino acid region of thrombopoietin.
Synonyms
Human EPO-alpha, EPO-alpha, EPO alpha, EPOalpha, h-EPO-alpha, rh-AEPO-alpha, recombinant human EPO-alpha, recombinant EPO-alpha, EPO.
Formulation
Lyophilized after extensive dialysis against PBS.
Reconstitution
Reconstituted in ddH2O or PBS at 100 μg/ml.
Storage
Lyophilized recombinant human EPO remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhEPO should be stable up to 1 week at 4°C or up to 2 months at -20°C.
Note
For research use only
Document-COA
  • B60011211_Z02975_COA.pdf
  • B60031406_Z02975_COA.pdf
  • 1
    Custom Recombinant Protein Services: Guaranteed E. coli Expression Package-3 mg purified soluble protein from $2,200 .
    2
    Bacterial Expression System: GenScript has developed BacPowerTM technologies to tackle hard-to-express and hard-to-dissolve proteins.
    3
    Yeast Expression System: GenScript's proprietary YeastHIGHTM technology combines the advantages of the bacterial and eukaryotic expression systems.
    4
    Baculovirus/Insect Cell Expression System: GenScript developed BacuVanceTM platform for the secretion of recombinant proteins from baculovirus-infected insect cells.
    5
    Mammalian Cell Expression System: The proprietary 293 and CHO suspension system platform promotes fast production and delivery of recombinant proteins and monoclonal antibodies up to grams level.